Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

The FDA has scuttled Merus’ plans to win a speedy approval for i | The FDA has scuttled Merus’ plans to win a speedy approval ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...

Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a ...